Hôpital Paris Saint Joseph
Paris, France
Location status: Recruiting
Location contact
Juliette COURTIADE MAHLER
CONTACT
Quentin MARTEL, MD
PRINCIPAL_INVESTIGATOR
NCT Number: NCT07086599
Chronic inflammatory rheumatisms (CIR) are a source of motor disability and various comorbidities, particularly cardiovascular and metabolic. They also significantly impact patients' quality of life, including sleep disturbances. Among CIRs, psoriatic arthritis is a chronic inflammatory arthropathy associated with psoriasis, typically seronegative for rheumatoid factor. This heterogeneous disease affects peripheral and/or axial joints and can include extra-articular manifestations such as uveitis and chronic inflammatory bowel diseases. Its prevalence is estimated between 0.3% and 1% in the general population.
SAPHO syndrome, similar to psoriatic arthritis, is characterized by specific bone involvement with a hypertrophic tendency, often affecting the axial skeleton and the anterior thoracic wall. Pain and inflammation are closely linked to sleep quality, creating a vicious cycle where pain disrupts sleep and poor sleep amplifies pain perception. Analgesic treatments, such as opioids, can also cause nocturnal respiratory pathologies, further disrupting sleep.
Inflammatory processes are regulated by sleep, influencing plasma concentrations of CRP, IL6, and TNF production. Patients with psoriatic arthritis or SAPHO syndrome share common risk factors with Obstructive Sleep Apnea Syndrome (OSAS), such as obesity, hypertension, and metabolic syndrome.
Sleep disorders are common in the general population and likely underdiagnosed in these patients. Several studies suggest a link between sleep disorders and these rheumatic conditions, affecting quality of life and exacerbating symptoms. Questionnaires like the Epworth and Pichot scales provide a more precise evaluation of these symptoms. However, objective sleep exploration through polysomnography has never been conducted in these patients.
In summary, CIRs, particularly psoriatic arthritis and SAPHO syndrome, significantly impact patients' quality of life and sleep, necessitating appropriate evaluation and management of associated sleep disorders.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Paris, France
Location status: Recruiting
Juliette COURTIADE MAHLER
CONTACT
Quentin MARTEL, MD
PRINCIPAL_INVESTIGATOR
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: at 6months
sleep disorders will be defined after polysomnography exam.
Time frame: at 6 months
quantity of the different sleep stages as observed on the polysomnography exam
Time frame: at enrollement
mesured by the PICHOT questionnar
Time frame: at enrollement
mesured by HAD questionnaire
Time frame: at enrollement
mesured with the Epworth Scale
Time frame: at enrollement, at 6months and at 12 months
mesured with the STOP BANG questionnaire
Time frame: at enrollemnt, 6months and 12 months after
mesured by the Apnea/hypopnea index
Time frame: at enrollement, after 6 months and after 12 months
mesured with the DPASA score
Time frame: at enrollment, 6months and 12 months after
expressed in mg/L
Contact information is provided by the study sponsor or research team.
Fondation Hôpital Saint-Joseph
Other
Acronym: SleepSO2
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07149792
Arthritis, Arthritis, Psoriatic
Taichung, Taiwan
View Trial DetailsNCT07132333
Arthritis, Bone Diseases
Tübingen, Germany
View Trial DetailsNCT06974474
Psoriasis Arthritis
Rome, Italy
View Trial DetailsNCT06905028
Behavior, Fasting
Berlin, State of Berlin, Germany
View Trial Details